Objective: To perform a cross-sectional study to determine whether plasma neurofilament light chain (NfL) concentration is elevated in patients with Charcot-Marie-Tooth disease (CMT) and if it correlates with disease severity.
Methods: Blood samples were collected from 75 patients with CMT and 67 age-matched healthy controls over a 1-year period. Disease severity was measured using the Rasch modified CMT Examination and neuropathy scores. Plasma NfL concentration was measured using an in-house-developed Simoa assay.
Results: Plasma NfL concentration was significantly higher in patients with CMT (median 26.0 pg/mL) compared to healthy controls (median 14.6 pg/mL, < 0.0001) and correlated with disease severity as measured using the Rasch modified CMT examination ( = 0.43, < 0.0001) and neuropathy ( = 0.37, = 0.044) scores. Concentrations were also significantly higher when subdividing patients by genetic subtype (, , and ) or into demyelinating or axonal forms compared to healthy controls.
Conclusion: There are currently no validated blood biomarkers for peripheral neuropathy. The significantly raised plasma NfL concentration in patients with CMT and its correlation with disease severity suggest that plasma NfL holds promise as a biomarker of disease activity, not only for inherited neuropathies but for peripheral neuropathy in general.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818017 | PMC |
| http://dx.doi.org/10.1212/WNL.0000000000004932 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating neurofilament light chain serum levels as a diagnostic marker for Lyme neuroborreliosis.
Ther Adv Neurol Disord
January 2025
Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Background: Serum neurofilament light chain (sNfL) is a biomarker for neuro-axonal injury.
Objectives: To assess sNfL's utility as a diagnostic marker for Lyme neuroborreliosis (LNB).
Methods: We compared serum and CSF NfL levels in LNB patients and age-matched controls.
Serum NfL predicts outcome and secondary autoimmunity in herpes-simplex encephalitis.
J Neuroimmunol
January 2025
Institute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck, Germany.
Objectives: Herpes simplex virus 1 encephalitis (HSE) is the most common infectious encephalitis in developed countries. We aimed to evaluate the association of serum neurofilament light chain (sNfL) with disease severity, outcome and secondary anti-neuronal autoantibodies in a retrospective cohort study.
Methods: We retrospectively identified 30 patients with HSE and 132 controls (bacterial meningoencephalitis BM n = 27, non-bacterial meningitis NBM n = 33, healthy controls = 72).
Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study.
Lupus Sci Med
January 2025
Institute of Rheumatology, Prague 2, Czech Republic
Background: The neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and serum as a marker of neuronal damage may be a potential biomarker of neuropsychiatric involvement in SLE (NPSLE).
Methods: 80 patients with SLE were included.We obtained paired serum and CSF samples from 48 patients (NPSLE n=32, non-NPSLE n=16) and 31 controls.
Higher plasma total tau concentrations among patients reporting CNS-related side effects from antiseizure medication.
Seizure
January 2025
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Department of Neurology, Sahlgrenska University Hospital, member of ERN Epicare, Gothenburg, Sweden; Wallenberg Center of Molecular and Translational Medicine, Gothenburg University, Sweden.
Background: Side effects from antiseizure medication (ASM) are common in epilepsy but biomarkers for detection and monitoring are missing. This study investigated associations between CNS-related side effects from ASM and blood concentrations of the brain injury markers neurofilament-light (NFL), total tau, glial acidic fibrillary protein (GFAP), S100 calcium-binding protein B (S100B) and neuron-specific enolase (NSE).
Methods: This is a population-based cohort study of adults with epilepsy recruited from five Swedish outpatient neurology clinics from December 2020 to April 2023.
Introduction: Age-associated depletion in nicotinamide adenine dinucleotide (NAD+) concentrations has been implicated in metabolic, cardiovascular, and neurodegenerative disorders. Supplementation with NAD+ precursors, such as nicotinamide riboside (NR), offers a potential therapeutic avenue against neurodegenerative pathologies in aging, Alzheimer's disease, and related dementias. A crossover, double-blind, randomized placebo (PBO) controlled trial was conducted to test the safety and efficacy of 8 weeks' active treatment with NR (1 g/day) on cognition and plasma AD biomarkers in older adults with subjective cognitive decline and mild cognitive impairment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!